MX2023007867A - Composicion de bl-8040. - Google Patents

Composicion de bl-8040.

Info

Publication number
MX2023007867A
MX2023007867A MX2023007867A MX2023007867A MX2023007867A MX 2023007867 A MX2023007867 A MX 2023007867A MX 2023007867 A MX2023007867 A MX 2023007867A MX 2023007867 A MX2023007867 A MX 2023007867A MX 2023007867 A MX2023007867 A MX 2023007867A
Authority
MX
Mexico
Prior art keywords
composition
retention time
relative retention
seq
treating
Prior art date
Application number
MX2023007867A
Other languages
English (en)
Inventor
Ella Sorani
Amnon Peled
Efrat Halbfinger
Original Assignee
Biolinerx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolinerx Ltd filed Critical Biolinerx Ltd
Publication of MX2023007867A publication Critical patent/MX2023007867A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Structures Or Materials For Encapsulating Or Coating Semiconductor Devices Or Solid State Devices (AREA)

Abstract

En el presente documento se desvela una composición que comprende BL-8040 (SEQ ID NO: 1), que puede ser para su uso en el tratamiento de una afección que se puede tratar mediante BL-8040. La composición comprende además al menos un compuesto caracterizado por un tiempo de retención relativo de 0,86 a 0,88 y/o un tiempo de retención relativo de 0,71 a 0,73 (en la que el tiempo de retención relativo de BL-8040 es 1) en las condiciones descritas en el presente documento.
MX2023007867A 2020-12-30 2021-12-29 Composicion de bl-8040. MX2023007867A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063131871P 2020-12-30 2020-12-30
PCT/IL2021/051548 WO2022144885A1 (en) 2020-12-30 2021-12-29 Composition of bl-8040

Publications (1)

Publication Number Publication Date
MX2023007867A true MX2023007867A (es) 2023-07-10

Family

ID=82260305

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007867A MX2023007867A (es) 2020-12-30 2021-12-29 Composicion de bl-8040.

Country Status (10)

Country Link
US (2) US20240082348A1 (es)
EP (1) EP4271402A1 (es)
JP (1) JP2024501709A (es)
KR (1) KR20230137345A (es)
CN (1) CN116801896A (es)
AU (1) AU2021412499A1 (es)
CA (1) CA3205658A1 (es)
IL (1) IL304159A (es)
MX (1) MX2023007867A (es)
WO (1) WO2022144885A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021412389A1 (en) 2020-12-30 2023-08-10 Biolinerx Ltd. Process for manufacturing peptide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003261723A1 (en) * 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
WO2012095849A1 (en) * 2011-01-10 2012-07-19 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma

Also Published As

Publication number Publication date
WO2022144885A1 (en) 2022-07-07
US20240131111A1 (en) 2024-04-25
CA3205658A1 (en) 2022-07-07
JP2024501709A (ja) 2024-01-15
US20240082348A1 (en) 2024-03-14
EP4271402A1 (en) 2023-11-08
AU2021412499A1 (en) 2023-08-10
IL304159A (en) 2023-09-01
KR20230137345A (ko) 2023-10-04
CN116801896A (zh) 2023-09-22

Similar Documents

Publication Publication Date Title
MX2021014350A (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.
MX2021013854A (es) Compuestos para tratar enfermedad de huntington.
MY141027A (en) Process for activating a hydrotreating catalyst
MX2023001450A (es) Composiciones y metodos para la inhibicion de la expresion de plp1.
YU101302A (sh) Derivat benzoilpiridina ili njegova so, fungicid koji ga sadrži u vidu aktivnog sastojka, postupak za njegovu proizvodnju i intermedijer za njegovo dobijanje
WO2018039462A8 (en) ALKALINE COMPOSITION FOR THE TREATMENT OF METALLIC SUBSTRATES
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
MX2023007867A (es) Composicion de bl-8040.
BR112022005757A2 (pt) Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma
FR3086943B1 (fr) Copolymere d'ethylene et de beta-farnesene
WO2022115798A3 (en) Compositions and methods for treating migraine
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
MX2022001952A (es) Compuestos de alquinil quinazolina.
NZ595231A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
MX2023010573A (es) Promotor minimo de nefrina.
MX2007011814A (es) Compuestos citoesqueleticos activos, composiciones y usos.
IL165259A0 (en) Compounds useful in the treatment of anthraxa and inhibiting lethal factor
ZA944164B (en) Zinc complexes in sulfur-vulcanized rubber compositions
WO2020160453A8 (en) Modulators of yap1 expression
MX2020008677A (es) Novedoso bacteriofago de salmonella heidelberg sal-hep-1 y su uso para inhibir el crecimiento de las bacterias de salmonella heidelberg.
MX2021010552A (es) Nuevo peptido y uso del mismo.
MX2020009495A (es) Potenciador de la expresion en plantas.
CR20230221A (es) Malonamidas herbicidas
MX2022013465A (es) Metodos para tratar eventos adversos relacionados con citocinas.
MX2023012086A (es) Composiciones y metodos para inhibir la expresion del miembro 3 del grupo h de la subfamilia 1 de receptores nucleares (nr1h3).